A detailed information about the drugs used in the treatment of the condition - hypertension.
Includes Classification, mechanism of action, side effects, dosage and indications of each classes of drugs.
presentation for drugs used to treat different types of angina pectoris : stable, unstable and vasospastic and the best for each type and side effects,
hypertension, simplified, jnc 8, treatment and newer modalities to treat. surgical procedures involved for hypertension and jnc 8 versus jnc 7 is compared in this ppt, and also, prevelance and epidemeiology of hypertension is explained. antihypertensives for preffered class and age are explained
A detailed information about the drugs used in the treatment of the condition - hypertension.
Includes Classification, mechanism of action, side effects, dosage and indications of each classes of drugs.
presentation for drugs used to treat different types of angina pectoris : stable, unstable and vasospastic and the best for each type and side effects,
hypertension, simplified, jnc 8, treatment and newer modalities to treat. surgical procedures involved for hypertension and jnc 8 versus jnc 7 is compared in this ppt, and also, prevelance and epidemeiology of hypertension is explained. antihypertensives for preffered class and age are explained
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Cardiovascular DRUGS.pptx
1.
2. What drug is given to decrease central sympathetic
outflow and norepinephrine release in noradrenergic
nerve endings but notorious in causing rebound
hypertension?
A. Guanabenz
B. Guanfacin
C. Clonidine
D. Amlodipine
3.
4. Control of blood pressure
• Physiologically, in both normal and hypertensive individuals,
blood pressure is maintained by moment-to-moment
regulation of cardiac output and peripheral vascular
resistance, exerted at three anatomic sites:
• Arterioles
• Postcapillary venules (capacitance vessels)
• Heart
• Kidney
5.
6.
7.
8. • Methyldopa
• Clonidine
• Guanabenz/Guanfacine
Activate central
a2 adrenoceptors
• Decrease central sympathetic outflow
• Decrease norepinephrine release in noradrenergic nerve
endings
10. What drug is given to decrease central sympathetic
outflow and norepinephrine release in noradrenergic
nerve endings but notorious in causing rebound
hypertension?
A. Guanabenz
B. Guanfacin
C. Clonidine
D. Amlodipine
11. What drug is given to decrease central sympathetic
outflow and norepinephrine release in noradrenergic
nerve endings but notorious in causing rebound
hypertension?
A. Guanabenz
B. Guanfacin
D. Amlodipine
12. •Adz experienced tremor, slurred speech, and
akathesia. Which of the following anti-
hypertensive medication is the culprit of this
manifestation?
A. Reserpine
B. Guanfacin
C. Guanabenz
D.All of the above
13. • Reserpine- Blocks vesicular amine transporter in noradrenergic nerves
• Guanethidine- replaces norepinephrine in the vesicles
Reduces sympathetic activity
Side effects:
mild diarrhea GIT cramps
increases gastric acid secretion sedation
lassitude nightmares
severe mental depression EPS
14. •Adz experienced tremor, slurred speech, and
akathesia. Which of the following anti-
hypertensive medication is the culprit of this
manifestation?
A. Reserpine
B. Guanfacin
C. Guanabenz
D.All of the above
15. •Adz experienced tremor, slurred speech, and
akathesia. Which of the following anti-
hypertensive medication is the culprit of this
manifestation?
B. Guanfacin
C. Guanabenz
D.All of the above
16. • Amy has to undergo Total Abdominal Bilateral Salpingo-Oophorectory,
intraoperatively her BP shoots up to 160/100. What particular beta
blocker must be given to Amy?
A. Betaxolol
B. Metoprolol
C. Atenolol
D. Esmolol
17.
18.
19.
20. • Amy has to undergo Total Abdominal Bilateral Salpingo-Oophorectory,
intraoperatively her BP shoots up to 160/100. What particular beta
blocker must be given to Amy?
A. Betaxolol
B. Metoprolol
C. Atenolol
D. Esmolol
21. • Amy has to undergo Total Abdominal Bilateral Salpingo-Oophorectory,
intraoperatively her BP shoots up to 160/100. What particular beta
blocker must be given to Amy?
A. Betaxolol
B. Metoprolol
C. Atenolol
22. •Annina was hypertensive, she was given with a
calcium channel blocker. Which calcium channel
blocker must be given to her?
A. Felodipine
B. Verapamil
C. Diltiazem
D. Any of the above
25. DIHYDROPYRIDINE
-dipine
• more selective as
vasodilator
• reflex SNS
activation with
slight tachycardia
NON-
DIHYDROPYRIDINE
-Verapamil
- Diltiazem
• Cardiac
depressant
26. •Annina was hypertensive, she was given with a
calcium channel blocker. Which calcium channel
blocker must be given to her?
B. Verapamil
C. Diltiazem
D. Any of the above
27. • Amy 27 years old, G1 at 25 weeks age of gestation
complained of stiff neck and dizziness. She check her BP and
ranges from 140-150/90-100 mmHg. She seek consult and
urinalysis was done with 3+ proteinuria. What is the drug of
choice to her condition that dilates arterioles but not veins?
A. Methyldopa
B. Hydralazine
C. Nitroprusside
D. Both A and B
28.
29.
30. • Amy 27 years old, G1 at 25 weeks age of gestation
complained of stiff neck and dizziness. She check her BP and
ranges from 140-150/90-100 mmHg. She seek consult and
urinalysis was done with 3+ proteinuria. What is the drug of
choice to her condition that dilates arterioles but not veins?
A. Methyldopa
C. Nitroprusside
D. Both A and B
38. • Innabels is diabetic and has gout. Which of the following
diuretic is are contraindicated with Innabels?
1. Furosemide 3. Hydrochlothiazide
2. Spironolactone 4. Eplerenone
A. 1,2
B. 1, 3
C. 3 only
D. ALL OF THE ABOVE
39.
40.
41. LOOP of HENLE
•Reabsorption of Sodium,
Potassium, chloride via
the NKCC2 carrier
•Major site of magnesium
and calcium reabsorption
•Thick ascending limb is
impermeable to water.
49. • Innabels is diabetic and has gout. Which of the following
diuretic is are contraindicated with Innabels?
1. Furosemide 3. Hydrochlothiazide
2. Spironolactone 4. Eplerenone
A. 1,2
B. 1, 3
C. 3 only
D. ALL OF THE ABOVE
50. • Innabels is diabetic and has gout. Which of the following
diuretic is are contraindicated with Innabels?
1. Furosemide 3. Hydrochlothiazide
2. Spironolactone 4. Eplerenone
A. 1,2
B. 1, 3
D. ALL OF THE ABOVE
52. Angina Pectoris
•Strangling or pressure-like pain due to cardiac
ischemia
•Substernal But may radiate to neck, shoulder,
arm, epigastrium
Types:
•Effort/ Classic Angina
•Vasospastic/Variant/ Prinzmetal angina
57. Release of NO within muscle cells
is probably due to the action of
mitochondrial enzyme aldehyde
dehydrogenase 2
58.
59.
60.
61. • Nicorandil
• Nicotinamide nitrate ester
• Decreases preload and afterload
• Provides myocardial protection by activation of cardiac
potassium ATP channels
• Ranolazine
• Reduces a late sodium current that facilitates calcium
entry via the sodium- calcium exchanger
• reduces diastolic tension, cardiac cotractility and work
• SE: prolongs the QT interval in patients with CAD
62. • Trimetazidine
• pFOX inhibitors because they partially inhibit fatty acid
oxidation pathway in myocardium
• Allopurinol
• Xanthine oxidade inhibitor
• prolongs exercise time in patients with atherosclerotic
plaque.
63. • Ivabradine
• relatively selective If, sodium channel blockers
• reduces the heart rate by inhibiting the hyperpolarization-
activated Na channels
• efficiency is similar with calcium channel blockers and
beta blockers
• Fasudil
• inhibitor of smooth muscle Rho kinase
65. Treatment
• Control of hyperlipidemia, hypotension, obesity,
diabetes
• Cessation of smoking
• Physical therapy and exercise training
• Percutaneous angioplasty with stenting
• antiplatelets
81. OTHER HELPFUL DRUGS
•B1 Agonist- Dobutamine, Dopamine
•Beta Blockers- Only if there is Marked
Tachycardia
•PDE5 Inhibitor: Sildenafil; Do NOT COMBINE
WITH NITRATES
•Novel Therapy- ARNI- LCZ696
Constriction of arterioles increases resistance, which causes a decrease in blood flow to downstream capillaries and a larger decrease in blood pressure.
VMAT-
Bradykinin substance P and neuro peptide gamma
compete with OAT 1 in eliminating uric acid
xanthine oxidase- enzyme that contribute to oxidative stress and endothelial dysfunction
pain occuring in skeletal muscles, especially in the legs, during exercise and disappears with rest